Antibody therapy

Today, antibodies have been developed to treat an increasing number of cancers that affect a larger proportion of patients and make a significant contribution to overall or disease-free survival as part of a combination regimen with established cytotoxic chemotherapies. The vast majority of antibodies are given as part of a combination chemotherapy regimen to realize their full potential. Different enhancing approaches are designed to create more potent antibodies that work better in combination or possibly as single agent therapy. Humanized monoclonal antibodies have changed the cancer treatment pattern over the past decade. Both in solid and hematologic tumors, antibodies have become an integral component of treatment regimens that have improved and extended the lives of cancer patients. In addition, antibodies have been able to improve efficacy while not significantly adding more toxicity.

  • Radioimmunotherapy
  • Antibody-directed enzyme prodrug therapy
  • Antibody-drug conjugates
  • Immunoliposome therapy
  • Checkpoint therapy

    Antibody therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in